Filling Tresiba® prescriptions: What you need to know


Tresiba® is a once-daily, long-acting insulin indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.See facts below.
 

Tresiba® FlexTouch® comes in 2 dose formulations: U-200 and U-100.1

Tresiba® FlexTouch® U‑100

FlexTouch® U-100 box
Concentration

100 units/mL

Pens per package

5

Volume per pen

3 mL

Units of insulin per pen

300 units

Units of insulin per package

1500 units

Max dose per injection

80 units

Dose increments

1 unit

NDC number

0169-2660-15


Tresiba® FlexTouch® U‑200

FlexTouch® U-200 box
Concentration

200 units/mL

Pens per package

3

Volume per pen

3 mL

Units of insulin per pen

600 units

Units of insulin per package

1800 units

Max dose per injection

160 units

Dose increments

2 unit

NDC number

0169-2550-13


Other facts about Tresiba®1:

Injected subcutaneously once daily, and for adults, at any time of day

  • Instruct adult patients who miss a dose of Tresiba® to inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule
  • Tresiba® must be dosed at the same time each day for pediatric patients. Instruct pediatric patients who miss a dose of Tresiba® to contact their health care provider for guidance and to monitor blood glucose levels more frequently until the next scheduled dose
  • Instruct patients to ensure that at least 8 hours have elapsed between consecutive Tresiba® injections

The recommended time between dose increases is 3 to 4 days

  • No dose conversion needed

The dose window for both the Tresiba® U-100 and U-200 pens shows the number of units to be delivered

  • Opened (in-use) Tresiba can be kept at room temperature (below 86°F), away from direct heat and light, or refrigerated (36°F to 46°F)
Eligible patients pay as little as $15 per prescriptiona

aFor up to 24 months. Maximum savings of $500 per prescription. Eligibility and other restrictions apply.


Don’t forget to order
NovoFine® Plus disposable needles

The 32G, 4 mm pen needle is designed to help make injections more comfortable.b



Give your patients a game plan with the Diabetes Health Coach


Cornerstones4Care® with blue grey letters

Hand phone icon

Live calls from a Certified Diabetes Educator for the first 90 days of therapy for patients with diabetes starting Tresiba®, available in both English and Spanish.c


Blue computer icon

Personalized online coaching sessions on more than 25 topics—developed by leading diabetes experts.


Blue phone and envelope

Ongoing support that includes tools, education, interactive trackers, and diabetes-friendly recipes.

Encourage patients taking Tresiba® to register for personalized support.



Dive deeper into Tresiba®


See what to do when patients miss their scheduled dose of Tresiba®

Find out which Tresiba® FlexTouch® pen is right for your patients

bNeedles are sold separately and may require a prescription in some states.

cPatients with diabetes qualify for live phone support if they have been taking Tresiba® for less than 6 months and requested calls when registering for Cornerstones4Care®.

Selected Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening

Indications and Usage

Tresiba® (insulin degludec injection) is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use

Tresiba® is not recommended for treating diabetic ketoacidosis or for pediatric patients requiring less than 5 units of Tresiba®.

Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
  • Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba®
  • As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered

Adverse Reactions

  • Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain

Drug Interactions

  • Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs and symptoms of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine)

Please click here for Prescribing Information.

 

Reference:

  1. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; December 2016.